Subscribe to Blue Jet Healthcare: KR Choksey

KR Choksey IPO report on Blue Jet Healthcare

Blue Jet Healthcare Ltd., founded in 1968 by Shri B.L. Arora, is a specialty pharmaceutical and healthcare ingredients and intermediate company, offering niche products, supplied to innovator and generic pharmaceutical companies as a Contract Development and Manufacturing Organization (CDMO) with specialization in contrast media intermediates and high intensity sweeteners. The company caters to 400 long term customers, across 39 countries, by engaging in multi-year contracts of up-to 5 years. The company offers three set of products including contrast media intermediates, high intensity sweeteners, pharma intermediates and Active Pharma Intermediates (APIs). The contrast media agents enable medical imaging to enhance visibility of body tissues under X-rays, computed tomography (CT) and magnetic resonance imaging (MRI) or ultrasound. The high intensity sweeteners includes development, manufacture, and marketing of saccharin and its salts.

Valuation and Outlook

We believe the coveted position in niche segments such as contrast media and sweeteners and planned capacity additions coupled with backward integration plans should help it grow its profitability further in the foreseeable future considerably. As a result, we recommend that Blue Jet Healthcare Ltd. IPO be rated ‘SUBSCRIBE'.